Chaim Hurvitz, Director at NRX Pharmaceuticals, Inc. (NRXP), bought 959,592 shares at $0.99 ($985K) on 2022-11-16, disclosed to the SEC on 2022-11-23.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.99 | 287,812 | $285K | 28.9% |
| 2 | $0.99 | 287,812 | $285K | 28.9% |
| 3 | $1.08 | 171,780 | $186K | 18.8% |
| 4 | $1.08 | 171,780 | $186K | 18.8% |
| 5 | $1.10 | 40,408 | $44K | 4.5% |
| Total | $1.03 avg | 959,592 |
| $985K |
| 100% |